Does Medicare Cover Ozempic? (2026 Answer)

Full answer: Medicare Part D covers Ozempic (semaglutide) when it is prescribed for type 2 diabetes. Part D does NOT cover Ozempic when prescribed solely for weight loss, because the Medicare Modernization Act of 2003 bars coverage of drugs used for weight gain or weight loss under SSA section 1927(d)(2)(A). Medicare Part B does not cover Ozempic at all (it is a self-administered outpatient drug). In 2026, most Medicare Part D beneficiaries with a diabetes diagnosis pay roughly $25 to $150 per month for Ozempic after their deductible, with a $2,100 annual out-of-pocket cap on all covered drugs.

Ozempic (semaglutide) is one of the most prescribed drugs in the United States, used by millions of people for type 2 diabetes and, increasingly, for weight loss. If you are on Medicare and your doctor prescribes Ozempic, whether Medicare pays for it depends entirely on the diagnosis it is being prescribed for.

The rule in 2026 is straightforward: Medicare Part D covers Ozempic for type 2 diabetes, full stop. It does not cover Ozempic for weight loss or obesity because a 2003 federal law still bars Medicare from covering anti-obesity drugs when used for weight management alone. This page explains the coverage rules, what you will pay out-of-pocket, and what alternatives exist if you need coverage for a weight-loss purpose. Medicaid coverage of GLP-1 drugs for obesity varies by state and is covered separately.

Coverage Breakdown

Coverage by type
Medicare Coverage	Ozempic for Type 2 Diabetes	Ozempic for Weight Loss
Part A (Hospital)	No	No
Part B (Outpatient/Medical)	No	No
Part D (Prescription Drugs)	Yes (with prior auth)	No (statutory exclusion)
Medicare Advantage (Part C)	Yes (most plans, with prior auth)	No (unless plan adds it)
Medigap (Supplement)	No (does not cover drugs)	No

Prior authorization is required by most Part D plans for Ozempic. Your plan may also require step therapy (trying metformin first). Check your plan formulary at Medicare.gov Plan Compare.

Source: CMS.gov, Medicare.gov Part D Drug Coverage, MMA 2003 SSA section 1927(d)(2)(A)

Why Medicare Covers Ozempic for Diabetes but Not Weight Loss

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) created Medicare Part D but explicitly excluded drugs used for anorexia, weight loss, or weight gain. This exclusion is codified in Social Security Act section 1927(d)(2)(A). When Congress wrote that law, few effective weight-loss drugs existed, and the exclusion has remained on the books for over two decades.

Ozempic received FDA approval to treat type 2 diabetes in December 2017. Because that is a medically accepted indication separate from weight loss, Medicare Part D can and does cover Ozempic for diabetes. The same molecule, Wegovy (at a higher dose), received FDA approval in June 2021 specifically for chronic weight management. CMS determined that Wegovy could not be covered for weight loss under standard Part D because of the MMA exclusion, until a new cardiovascular indication changed the equation in March 2024.

Wegovy and the March 2024 Cardiovascular Coverage Rule

In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease who are also obese or overweight. CMS immediately issued guidance that Medicare Part D plans may cover Wegovy for this cardiovascular indication, because the drug is now treating heart disease rather than solely weight. This matters for Ozempic users because it opened a limited path for people with heart disease.

If you have established cardiovascular disease (prior heart attack, prior stroke, or symptomatic peripheral artery disease) and you are overweight or obese, ask your doctor whether Wegovy is appropriate. Most Part D plans can cover it under that cardiovascular indication. Your plan may still require prior authorization and impose cost-sharing based on its tier placement. See Wegovy cost without insurance for a full breakdown of list price and savings options.

New in 2026: The Medicare GLP-1 Bridge Program

Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a demonstration program running through December 31, 2027. The Bridge offers Medicare Part D beneficiaries access to certain GLP-1 weight-loss drugs at a flat $50 per month copayment. This is a significant policy shift, but it does NOT include Ozempic.

The Bridge covers Wegovy (all formulations), Zepbound (KwikPen only), and Foundayo for weight management purposes. Ozempic is excluded from the Bridge because it does not have an FDA approval specifically for weight loss or chronic weight management. To qualify for the Bridge, you must be enrolled in a Part D plan, have a BMI of 30 or higher (or 27 or higher with a qualifying condition such as pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease), and your provider must submit a prior authorization.

Eligible drugs: Wegovy (all formulations), Zepbound (KwikPen), Foundayo
NOT included: Ozempic, Mounjaro, Rybelsus (for weight-loss purposes)
Cost: $50 flat monthly copay (does NOT count toward the $2,100 annual OOP cap)
Dates: July 1, 2026 through December 31, 2027
Requires prior authorization from your provider

What You Will Pay for Ozempic Under Medicare Part D in 2026

Ozempic is a brand-name drug with no generic equivalent available. Generic semaglutide is not expected until the mid-2030s due to patent protections. Most Part D plans place Ozempic on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which affects your cost-sharing.

In 2026, the Part D annual out-of-pocket cap is $2,100. Once your total covered drug spending reaches that threshold, you pay $0 for the rest of the year. Manufacturer copay cards like the Novo Nordisk savings card are prohibited for Medicare Part D beneficiaries under federal anti-kickback rules, so they will not reduce your Part D cost-sharing.

Typical Ozempic out-of-pocket costs under Medicare Part D 2026
Coverage Phase	What You Pay	Notes
Deductible phase	Full price (up to $1,029/month list price)	Until annual deductible is met; many plans have $0 deductible for Tier 1-2 drugs but not Tier 3-4
Initial coverage phase	$25 to $150/month (25% coinsurance or plan copay)	After deductible; amount depends on plan tier and coinsurance structure
Catastrophic phase	$0 for the rest of the year	After annual out-of-pocket reaches $2,100 cap

Ozempic list price (WAC) is roughly $1,029 per month in 2026. Negotiated prices vary by plan. The Part D OOP cap took effect January 1, 2025 at $2,000 under the Inflation Reduction Act; the 2026 cap is $2,100.

Source: CMS Medicare Part D 2026 rules, Novo Nordisk prescribing information

You may qualify for free health insurance.

Our 2-minute screener checks Medicaid, ACA, Medicare, CHIP, and more. Most uninsured Americans qualify for $0/month coverage they didn't know about.

Check what I qualify for — free

How to Navigate Prior Authorization and Tier Exceptions

Most Part D plans require prior authorization for Ozempic, meaning your doctor must submit documentation confirming you have type 2 diabetes before the plan approves coverage. Some plans also require step therapy, which means you must try and fail a less expensive diabetes drug (often metformin) before the plan covers Ozempic. Your doctor must document that you tried the required drug and it was insufficient or not tolerated.

If your plan places Ozempic on a non-formulary tier or denies it entirely for your diagnosis, you can request a formulary exception or coverage determination. You have the right to appeal any Part D denial. Work with your doctor to submit a letter of medical necessity explaining why Ozempic is specifically required. CMS requires plans to respond to standard coverage determinations within 72 hours and to expedited requests within 24 hours.

Step 1: Have your doctor submit a prior authorization request with diabetes diagnosis codes (E11.xx)
Step 2: If denied for step therapy, have your doctor document prior drug trials and failures
Step 3: If denied, file a formulary exception or appeal within 60 days of the denial notice
Step 4: If the internal appeal fails, request an Independent Review Entity (IRE) review
Check formulary coverage using the Medicare Plan Finder at medicare.gov

GLP-1 Alternatives for Medicare Patients

If your goal is weight loss and you do not have type 2 diabetes or qualifying cardiovascular disease, you have limited options under standard Medicare in 2026. The GLP-1 Bridge program (Wegovy, Zepbound, Foundayo at $50/month) is your best new option starting July 2026 if you meet the BMI and clinical criteria. Here is how the main GLP-1 options compare for Medicare patients.

GLP-1 drug Medicare coverage comparison 2026
Drug	Active Ingredient	Medicare Covers For	Notes
Ozempic	Semaglutide (weekly injectable)	Type 2 diabetes (Part D)	NOT covered for weight loss
Wegovy	Semaglutide (higher dose)	Cardiovascular risk reduction in CVD patients; weight loss via GLP-1 Bridge (July 2026)	Requires CVD diagnosis for standard Part D; $50/mo via Bridge
Mounjaro	Tirzepatide	Type 2 diabetes (Part D)	NOT covered for weight loss under standard Part D
Zepbound	Tirzepatide (higher dose)	Weight loss via GLP-1 Bridge (July 2026)	$50/mo via Bridge (KwikPen only); BMI criteria required
Trulicity	Dulaglutide	Type 2 diabetes (Part D)	Older GLP-1; often lower tier, lower cost

No generic semaglutide or tirzepatide is available in 2026. Patent exclusivity is expected to hold through the early 2030s.

Source: CMS Medicare GLP-1 Bridge, FDA drug approval database, KFF Medicare GLP-1 analysis

Dual-Eligible Strategy: Medicaid May Fill the Gap

About 12 million Americans qualify for both Medicare and Medicaid (dual-eligible). If you are dual-eligible, Medicaid pays your Part D cost-sharing, which can dramatically reduce your out-of-pocket cost for Ozempic. Medicaid also covers Ozempic for type 2 diabetes and, in states that have adopted the BALANCE Model, may cover GLP-1 drugs for obesity treatment. Medicaid has expanded in 40 states plus the District of Columbia, with income limits typically up to 138% of the federal poverty level.

If you are on Medicare and your income is near or below your state's Medicaid limit, use the eligibility screener below to check whether you qualify. Even partial Medicaid eligibility (a Medicare Savings Program that covers Part B premiums and cost-sharing) can reduce your overall drug costs significantly.

Frequently Asked Questions

Does Medicare cover Ozempic for type 2 diabetes?

Yes. Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes. Most Part D plans require prior authorization confirming your diabetes diagnosis before approving coverage. Some plans also require step therapy, meaning you must document a prior trial of a less expensive diabetes drug such as metformin. Check your specific plan formulary at medicare.gov/plan-compare for tier placement and cost details.

Does Medicare cover Ozempic for weight loss?

No. Medicare does not cover Ozempic for weight loss. The Medicare Modernization Act of 2003 bars Medicare Part D from covering drugs prescribed solely for weight gain or weight loss (Social Security Act section 1927(d)(2)(A)). This statutory exclusion applies even though Ozempic is widely used for weight management off-label. If weight loss is the goal, ask your doctor about Wegovy, Zepbound, or Foundayo, which may qualify under the Medicare GLP-1 Bridge starting July 2026.

What is the Medicare GLP-1 Bridge and does it cover Ozempic?

The Medicare GLP-1 Bridge is a CMS demonstration program running July 1, 2026 through December 31, 2027. It provides eligible Medicare Part D beneficiaries access to certain GLP-1 weight-loss drugs at a $50 monthly copay. Ozempic is NOT included in the Bridge because it does not have an FDA approval specifically for weight loss or chronic weight management. The Bridge covers Wegovy (all formulations), Zepbound (KwikPen), and Foundayo. The $50 copay does not count toward the $2,100 annual out-of-pocket cap.

Does Medicare cover Wegovy for weight loss?

Yes, in two scenarios. First, Medicare Part D can cover Wegovy when prescribed to reduce cardiovascular risk in patients with established cardiovascular disease who are overweight or obese (based on the March 2024 FDA approval). Second, starting July 1, 2026, the Medicare GLP-1 Bridge covers Wegovy for weight management at a $50 monthly copay for eligible beneficiaries with qualifying BMI and clinical criteria. Standard Medicare Part D does not cover Wegovy for weight loss alone outside these pathways.

What is the out-of-pocket cost for Ozempic on Medicare Part D in 2026?

Most Medicare Part D beneficiaries with type 2 diabetes pay roughly $25 to $150 per month for Ozempic during the initial coverage phase, depending on their plan's tier and coinsurance structure. During the deductible phase, you may pay full price (Ozempic list price is roughly $1,029 per month in 2026). Once your total annual drug spending reaches the $2,100 out-of-pocket cap, you pay $0 for covered drugs for the rest of the year. Manufacturer copay cards are prohibited for Medicare beneficiaries under federal law.

Does Medicare Part B cover Ozempic?

No. Medicare Part B covers drugs administered in a clinical setting by a provider, such as chemotherapy or certain injections given in a doctor's office. Ozempic is self-administered (you inject it yourself at home), so it is classified as a Part D outpatient prescription drug. Part A (hospital insurance) also does not cover Ozempic for outpatient use.

Can I appeal if my Medicare Part D plan denies Ozempic?

Yes. If your Part D plan denies Ozempic coverage or places it on a non-formulary tier, you have the right to request a coverage determination, file a formulary exception, and appeal through multiple levels including an Independent Review Entity (IRE). File within 60 days of the denial notice. Have your doctor submit a letter of medical necessity. CMS requires plans to respond to standard coverage requests within 72 hours and expedited requests within 24 hours.

Is there a generic version of Ozempic covered by Medicare?

No. There is no generic version of Ozempic (semaglutide) available in 2026. Novo Nordisk holds patents on semaglutide that are expected to prevent generic entry until the mid-2030s. Medicare Part D will cover Ozempic as a brand-name drug under its standard formulary rules. Some plans negotiate lower contracted prices than the list price, so your actual copay may be lower than the full list price even without a generic.